Shanshan Suo

Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy

Yinjun Lou, Yafang Ma, Shanshan Suo et al. · Leukemia Research · 2015 · 45 citations

Prognostic Factors, Hematological Malignancy, Medicine +8

<scp>K</scp>lf10 inhibits <scp>IL</scp>‐12p40 production in macrophage colony‐stimulating factor‐induced mouse bone marrow‐derived macrophages

Wei Zhang, Xuelian Wang, Xiaoping Xia et al. · European Journal of Immunology · 2012 · 32 citations

Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells

Jian Chen, Qitian Mu, Xia Li et al. · Oncotarget · 2017 · 31 citations · Full text

Hematological Malignancy, Virtual Screening, Mixed-phenotype Acute Leukemia +14

Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy

Yinjun Lou, Shanshan Suo, Hongyan Tong et al. · Leukemia Research · 2013 · 25 citations

Hematological Malignancy, Prognosis Analysis, Medicine +9

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia

Jie Jin, Jian Chen, Shanshan Suo et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2014 · 22 citations

Hematological Malignancy, Conventional Chemotherapy, Cytarabine Regimen +11